Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.
Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, has extended its series B round by €18m ($22m) thanks to its existing investor base.
These shareholders are European Molecular Biology Laboratory’s EMBL Ventures, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical firm Boehringer Ingelheim’s Venture Fund, Gimv Vesalius BioCapital III and BioMedPartners.
Topas previously obtained an initial $26m in series B funding in October 2020 co-led by Vesalius BioCaptial…
